Immunic

OverviewSuggest Edit

Immunic (previously known as Vital Therapies) is a biopharmaceutical company. It develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis.

TypePublic
Founded2003
HQNew York, NY, USMap
Websiteimmunic-therapeutics.com
Employee Ratings3.8More

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)26(+160%)
Revenue (FY, 2019)$0
Share Price (Sept 2021)$9.4(-2%)
Cybersecurity ratingAMore

Key People/Management at Immunic

Daniel Vitt

Daniel Vitt

CEO, President and Director
Duane Nash

Duane Nash

Executive Chairman
Hella Kohlhof

Hella Kohlhof

Chief Scientific Officer
Andreas Muehler

Andreas Muehler

Chief Medical Officer
Manfred Gröppel

Manfred Gröppel

Chief Operating Officer
Glenn Whaley

Glenn Whaley

Vice President Finance, Principal Financial and Accounting Officer
Show more

Immunic Office Locations

Immunic has offices in New York and Gräfelfing
New York, NY, US (HQ)
1200 6th Ave #200
Gräfelfing, DE
Lochhamer Schlag 21
Show all (2)

Immunic Financials and Metrics

Immunic Revenue

USD

Net income (Q1, 2021)

(34.5m)

EBIT (Q1, 2021)

(32.4m)

Market capitalization (14-Sept-2021)

205.1m

Closing stock price (14-Sept-2021)

9.4

Cash (31-Mar-2021)

114.8m

EV

91.2m
Immunic's current market capitalization is $205.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

Cost of goods sold

862.0k933.0k999.0k

General and administrative expense

10.9m12.3m11.2m13.3m13.6m14.5m10.3m

R&D expense

39.5m39.8m30.0m39.3m24.8m22.5m38.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

General and administrative expense

2.7m2.5m2.6m3.1m3.5m2.7m2.8m2.7m2.8m3.1m2.7m3.0m4.3m4.3m2.5m2.7m9.0m2.1m2.6m2.2m2.5m20.9m

R&D expense

9.2m9.1m10.2m11.8m11.5m9.6m6.9m6.9m7.5m9.6m9.8m9.7m10.2m8.7m6.0m494.0k6.0m7.1m6.4m10.0m11.0m11.5m

Operating expense total

11.9m11.6m12.8m14.8m15.1m12.3m9.7m9.5m10.2m12.7m12.5m12.6m14.5m12.9m8.5m3.2m15.0m9.2m9.0m12.2m13.5m32.4m

Depreciation and amortization

24.0k
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

102.2m83.4m60.0m56.9m13.3m29.4m127.5m

Prepaid Expenses

1.2m908.0k2.9m6.3m

Inventories

1.3m30.2m20.8m

Current Assets

104.8m85.1m61.5m58.1m14.2m32.2m133.7m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

46.0m90.8m79.1m88.3m71.9m59.8m77.9m73.6m68.1m86.6m76.2m66.4m43.6m31.1m17.8m9.6m36.1m30.5m18.6m48.6m133.2m114.8m

Prepaid Expenses

1.3m1.4m1.6m828.0k2.1m1.8m1.0m1.6m1.4m1.7m1.9m1.6m1.2m1.5m1.3m393.0k2.5m4.1m5.0m4.4m4.4m5.4m

Current Assets

52.3m93.5m82.6m90.6m75.4m62.6m79.2m75.4m69.5m88.3m78.1m68.0m44.8m32.6m19.1m10.0m39.5m34.5m23.6m53.0m137.5m120.3m

PP&E

3.1m3.3m3.0m4.1m4.2m4.2m3.4m3.0m2.9m2.5m2.4m2.3m2.1m2.1m890.0k482.0k43.0k44.0k77.0k121.0k147.0k190.0k
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(47.7m)(52.0m)(41.0m)(52.1m)(41.5m)(34.9m)(44.0m)

Depreciation and Amortization

1.1m1.3m1.8m998.0k727.0k50.0k39.0k

Inventories

(6.5m)

Accounts Payable

46.0k281.0k(459.0k)287.0k(770.0k)(462.0k)1.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(10.7m)(20.9m)(33.7m)(14.8m)(29.9m)(42.2m)(9.6m)(19.1m)(29.2m)(12.6m)(25.0m)(37.5m)(14.4m)(27.1m)(39.0m)(9.5m)(19.0m)(27.2m)(8.5m)(19.9m)(32.9m)(34.5m)

Depreciation and Amortization

297.0k543.0k853.0k294.0k622.0k947.0k494.0k984.0k335.0k564.0k780.0k224.0k424.0k628.0k217.0k29.0k38.0k14.0k20.0k63.0k14.0k

Accounts Payable

(58.0k)337.0k(142.0k)111.0k(62.0k)(397.0k)(361.0k)(360.0k)(120.0k)396.0k46.0k211.0k(145.0k)31.0k94.0k(83.0k)(1.4m)918.0k(973.0k)(676.0k)875.0k6.8m

Cash From Operating Activities

(9.4m)(19.2m)(30.4m)(13.5m)(28.6m)(40.7m)(10.0m)(18.8m)(26.7m)(10.9m)(21.1m)(30.5m)(13.1m)(25.4m)(38.5m)(3.7m)(16.3m)(22.3m)(11.0m)(20.3m)(32.2m)(12.9m)
show all
USDQ1, 2014

Financial Leverage

-1 x
Show all financial metrics

Immunic Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about our premium products
SecurityScorecard logo

Immunic Online and Social Media Presence

Immunic's Trends

Embed Graph

Immunic News and Updates

September 08, 2021

Immunic, Inc. to Participate in Investor and Scientific Conferences in September

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following...
August 06, 2021

Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

NEW YORK, Aug. 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the second...
July 12, 2021

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

NEW YORK, July 12, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that it will host a virtual R&D Day...
July 01, 2021

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

NEW YORK, July 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced U.S. Food and Drug Administration (FDA)...
June 28, 2021

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July

NEW YORK, June 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following...
June 10, 2021

Immunic, Inc. to Participate in Industry and Investor Conferences in June

NEW YORK, June 10, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following...
Show more

Immunic Blogs

March 27, 2019

Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG

Of the Votes Received to Date, More than 98% are Voting in Favor of the Business Combination More Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go Forward Every Vote is Important to Avoid Delay in Completion of the Business Combination SAN DIEGO ,
October 11, 2018

Vital Therapies Provides Strategic Update

Vital Therapies Provides Strategic Update Content Import Thu, 10/11/2018 - 09:29 Vital Therapies Provides Strategic Update October 11, 2018 at 9:27 AM EDT This release is a backfill from a News Wire General SAN DIEGO, Oct. 11, 2018 …
July 31, 2018

Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast

Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast Content Import Tue, 07/31/2018 - 16:03 Vital Therapies Announces Upcoming Second Quarter Financial Results Conference Call With Webcast July 31, 2018 at 4:01 PM EDT …

 Immunic Frequently Asked Questions

  • When was Immunic founded?

    Immunic was founded in 2003.

  • Who are Immunic key executives?

    Immunic's key executives are Daniel Vitt, Duane Nash and Hella Kohlhof.

  • How many employees does Immunic have?

    Immunic has 26 employees.

  • Who are Immunic competitors?

    Competitors of Immunic include Plasma Industries, The Searle Company and Serum Institute of India.

  • Where is Immunic headquarters?

    Immunic headquarters is located at 1200 6th Ave #200, New York.

  • Where are Immunic offices?

    Immunic has offices in New York and Gräfelfing.

  • How many offices does Immunic have?

    Immunic has 2 offices.